Staar surgical publishes presentation highlighting compelling, certain cash value offered by alcon merger and meaningful downside risks if alcon merger is not approved

Lake forest, calif.--(business wire)--staar surgical company (nasdaq: staa), the global leader in phakic iols with the evo family of implantable collamer® lenses (evo icl™) for vision correction, today published a presentation reviewing the compelling, certain, premium cash value offered by the company's pending merger with alcon (six/nyse: alc) and the meaningful downside risks for staar stockholders if the alcon merger is not approved. the presentation is available at investors.staar.com and.
ALC Ratings Summary
ALC Quant Ranking